We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Allegro is busy working to see its eye disease candidate risuteganib into the final stages of testing, and will now have a new chief to help it through phase 3 and, it hopes, beyond.